Novo Nordisk
-
{
- All
- News
- Videos
-
Novo Nordisk Bets On Once-Weekly China Developed Obesity Pill In Deal Worth $2.6 Billion
The deal covers HRS-1596, a drug candidate that targets two gut hormone receptors, glucagon-like peptide-1 (GLP-1R) and gastric inhibitory polypeptide (GIPR).
-
Novo Responds To GLP-1 Drug Ozempic Causing Vision Loss Claims: What Semaglutide Data Shows
Novo Nordisk says a large pooled analysis of clinical trials found no increased risk of rare NAION with semaglutide. Here is what the new evidence means for diabetes patients in India amid concerns over sudden vision loss.
-
Ozempic-Maker Novo Nordisk Slims Down To 'Novo'
Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Monday a name change to just Novo, hoping it will be more...
-
Novo Nordisk Launches Once-Weekly Insulin In India; Promises Competitive Pricing, Wider Access
Awiqli cuts basal insulin dosing from seven injections a week to one. Novo Nordisk India MD Vikrant Shrotriya discusses price, access and growth.
-
Novo Nordisk's Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
Patients taking zenagamtide saw a significant drop in their HbA1C levels. Higher doses, 40 mg, lowered HbA1C by up to 1.71 % compared to just a 0.14 drop in the placebo group.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
Novo Nordisk Bets On Once-Weekly China Developed Obesity Pill In Deal Worth $2.6 Billion
The deal covers HRS-1596, a drug candidate that targets two gut hormone receptors, glucagon-like peptide-1 (GLP-1R) and gastric inhibitory polypeptide (GIPR).
-
Novo Responds To GLP-1 Drug Ozempic Causing Vision Loss Claims: What Semaglutide Data Shows
Novo Nordisk says a large pooled analysis of clinical trials found no increased risk of rare NAION with semaglutide. Here is what the new evidence means for diabetes patients in India amid concerns over sudden vision loss.
-
Ozempic-Maker Novo Nordisk Slims Down To 'Novo'
Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Monday a name change to just Novo, hoping it will be more...
-
Novo Nordisk Launches Once-Weekly Insulin In India; Promises Competitive Pricing, Wider Access
Awiqli cuts basal insulin dosing from seven injections a week to one. Novo Nordisk India MD Vikrant Shrotriya discusses price, access and growth.
-
Novo Nordisk's Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
Patients taking zenagamtide saw a significant drop in their HbA1C levels. Higher doses, 40 mg, lowered HbA1C by up to 1.71 % compared to just a 0.14 drop in the placebo group.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
